Title : Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM\/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis - Martin_2015_Oncologist_20_111 |
Author(s) : Martin M , Martinez N , Ramos M , Calvo L , Lluch A , Zamora P , Munoz M , Carrasco E , Caballero R , Garcia-Saenz JA , Guerra E , Caronia D , Casado A , Ruiz-Borrego M , Hernando B , Chacon JI , De la Torre-Montero JC , Jimeno MA , Heras L , Alonso R , De la Haba J , Pita G , Constenla M , Gonzalez-Neira A |
Ref : Oncologist , 20 :111 , 2015 |
Abstract :
BACKGROUND: The approved capecitabine regimen as monotherapy in metastatic breast cancer (MBC) is 1,250 mg/m(2) twice daily for 2 weeks on and 1 week off (Cint). Dose modifications are often required because of severe hand-foot syndrome (HFS). We tested a continuous regimen with a lower daily dose but a similar cumulative dose in an attempt to reduce the severity of adverse events (AEs) while maintaining efficacy. |
PubMedSearch : Martin_2015_Oncologist_20_111 |
PubMedID: 25601966 |
Substrate | Capecitabine |
Martin M, Martinez N, Ramos M, Calvo L, Lluch A, Zamora P, Munoz M, Carrasco E, Caballero R, Garcia-Saenz JA, Guerra E, Caronia D, Casado A, Ruiz-Borrego M, Hernando B, Chacon JI, De la Torre-Montero JC, Jimeno MA, Heras L, Alonso R, De la Haba J, Pita G, Constenla M, Gonzalez-Neira A (2015)
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM\/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis
Oncologist
20 :111
Martin M, Martinez N, Ramos M, Calvo L, Lluch A, Zamora P, Munoz M, Carrasco E, Caballero R, Garcia-Saenz JA, Guerra E, Caronia D, Casado A, Ruiz-Borrego M, Hernando B, Chacon JI, De la Torre-Montero JC, Jimeno MA, Heras L, Alonso R, De la Haba J, Pita G, Constenla M, Gonzalez-Neira A (2015)
Oncologist
20 :111